Epstein-Barr virus (EBV), originally discovered through its association with Burkitt lymphoma, is now aetiologically linked to a remarkably wide range of lymphoproliferative lesions and malignant lymphomas of B-, T- and NK-cell origin. Some occur as rare accidents of virus persistence in the B lymphoid system, while others arise as a result of viral entry into unnatural target cells. The early finding that EBV is a potent B-cell growth transforming agent hinted at a simple oncogenic mechanism by which this virus could promote lymphomagenesis. In reality, the pathogenesis of EBV-associated lymphomas involves a complex interplay between different patterns of viral gene expression and cellular genetic changes. Here we review recent developments in our understanding of EBV-associated lymphomagenesis in both the immunocompetent and immunocompromised host. This article is part of the themed issue ‘Human oncogenic viruses’.
CITATION STYLE
Shannon-Lowe, C., Rickinson, A. B., & Bell, A. I. (2017, October 19). Epstein-barr virus-associated lymphomas. Philosophical Transactions of the Royal Society B: Biological Sciences. Royal Society Publishing. https://doi.org/10.1098/rstb.2016.0271
Mendeley helps you to discover research relevant for your work.